FDA approves Roche's Cotellic for combination skin cancer therapy
November 10, 2015 at 11:58 AM EST
ZURICH, Nov 10 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Swiss drugmaker Roche's Cotellic to be used in combination with the company's Zelboraf drug to treat BRAF V600 mutation-positive advanced melanoma.